Artelo Biosciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARTL Nasdaq 2830 artelobio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Artelo Biosciences, Inc.

Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success - Jun 10th, 2026 5:38 am
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results - May 14th, 2026 2:05 pm
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development - Apr 28th, 2026 6:25 am
Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile - Apr 20th, 2026 5:50 am
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements - Apr 7th, 2026 5:50 am
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Mar 30th, 2026 2:46 pm
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Mar 27th, 2026 8:40 am
BC-Most Active Stocks - Mar 27th, 2026 8:30 am
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments - Mar 25th, 2026 2:05 pm
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients - Mar 18th, 2026 5:41 am
Artelo Biosciences announces 3-for-1 reverse stock split - Mar 7th, 2026 6:13 am
Artelo Biosciences Announces Reverse Stock Split - Mar 6th, 2026 6:00 am
Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results - Feb 24th, 2026 6:00 am
Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate - Dec 23rd, 2025 7:00 am
Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models - Dec 3rd, 2025 6:30 am
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results - Nov 12th, 2025 6:00 am
Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer - Nov 4th, 2025 6:30 am
Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer - Oct 27th, 2025 6:00 am
Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit - Oct 15th, 2025 7:15 am
Artelo Biosciences Announces Closing of $2.0 Million Public Offering - Oct 1st, 2025 2:05 pm